nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Alignment of Competencies to Address Inefficiencies in Medicines Development and Clinical Research: Need for Inter-Professional Education
|
Silva, Honorio |
|
2015 |
|
3 |
p. 131-140 |
artikel |
2 |
Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch (Eds). Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development: A Focus on Early Phase Clinical Studies
|
Camastra, Stefania |
|
2016 |
|
3 |
p. 165-167 |
artikel |
3 |
An Investigation of Physicians’ Perception of Pharmaceutical Trade Names in Jordan’s Private Sector Using Real-World and Simulated Approaches
|
Al-Aqqad, Hamsa |
|
2015 |
|
3 |
p. 169-178 |
artikel |
4 |
Biotechnology Industry Organization — BIO 2006
|
Bardsley-Elliot, Anne |
|
|
|
3 |
p. 187-196 |
artikel |
5 |
Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?
|
Krentz, Andrew J. |
|
2014 |
|
3 |
p. 109-117 |
artikel |
6 |
Content Related to Older Adults in Canadian Innovator–Drug Product Monographs: An Exploratory Analysis
|
Babadagli, Hazal E. |
|
2016 |
|
3 |
p. 149-155 |
artikel |
7 |
Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue
|
Kotecki, Nuria |
|
2016 |
|
3 |
p. 143-147 |
artikel |
8 |
Drug in Clinical Development for Hepatitis C: Summary and Table
|
|
|
2014 |
|
3 |
p. 123-134 |
artikel |
9 |
Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical Hepatologist
|
Lewis, James H. |
|
2013 |
|
3 |
p. 165-191 |
artikel |
10 |
Drugs in Clinical Development for Psoriasis and Psoriatic Arthritis: Summary and Table
|
|
|
2013 |
|
3 |
p. 193-201 |
artikel |
11 |
Drugs in Clinical Development for Pulmonary Hypertension: Summary and Table
|
|
|
2015 |
|
3 |
p. 179-182 |
artikel |
12 |
Evaluation of Physician Knowledge of the Key Safety Information for Aflibercept in Canada: Evaluation of Risk-Minimization Measures
|
Zografos, Laurie J. |
|
2019 |
|
3 |
p. 235-246 |
artikel |
13 |
Evaluation of Two Strategies for Community-Based Safety Monitoring during Seasonal Malaria Chemoprevention Campaigns in Senegal, Compared with the National Spontaneous Reporting System
|
Ndiaye, Jean-Louis A. |
|
2018 |
|
3 |
p. 189-200 |
artikel |
14 |
Factors Associated with Drug-Related Emergency Department Visits at a Teaching Hospital in Malaysia
|
Ab Rahman, Ab Fatah |
|
2017 |
|
3 |
p. 175-181 |
artikel |
15 |
Forum
|
|
|
2013 |
|
3 |
p. 203-213 |
artikel |
16 |
Forum
|
|
|
2017 |
|
3 |
p. 183-207 |
artikel |
17 |
Forum
|
|
|
2016 |
|
3 |
p. 169-182 |
artikel |
18 |
Forum
|
|
|
2018 |
|
3 |
p. 219-237 |
artikel |
19 |
Forum
|
|
|
2015 |
|
3 |
p. 183-192 |
artikel |
20 |
Forum
|
|
|
2014 |
|
3 |
p. 135-147 |
artikel |
21 |
Forum
|
|
|
2019 |
|
3 |
p. 247-256 |
artikel |
22 |
Genome Editing: Promoting Responsible Research
|
Hirsch, François |
|
2019 |
|
3 |
p. 187-191 |
artikel |
23 |
Improving Asthma Outcomes in the Digital Era: A Systematic Review
|
Biblowitz, Kathleen |
|
2018 |
|
3 |
p. 173-187 |
artikel |
24 |
Incorporation of Abuse Potential Assessment into the Development of New Prescription Drugs
|
Mansbach, Robert S. |
|
2015 |
|
3 |
p. 141-153 |
artikel |
25 |
Influence of Breakthrough Therapy Designation in the United States on Oncology Drug Development Timelines in Japan
|
Tanaka, Makoto |
|
2018 |
|
3 |
p. 201-207 |
artikel |
26 |
Investigation into the Impact of Aging on Serious Adverse Events Associated with Antirheumatic Agents Using the Japanese Adverse Drug Event Report Database
|
Matsuoka, Yomei |
|
2018 |
|
3 |
p. 209-217 |
artikel |
27 |
Journal Watch
|
|
|
2013 |
|
3 |
p. 215-223 |
artikel |
28 |
Journal Watch
|
|
|
2014 |
|
3 |
p. 149-161 |
artikel |
29 |
Linking Death Certificates, Postmortem Toxicology, and Prescription History Data for Better Identification of Populations at Increased Risk for Drug Intoxication Deaths
|
Slavova, Svetla |
|
2017 |
|
3 |
p. 155-165 |
artikel |
30 |
Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data
|
Parigi, Angelo Del |
|
2019 |
|
3 |
p. 209-217 |
artikel |
31 |
Major Pharmaceutical Conferences and Courses
|
|
|
2017 |
|
3 |
p. 209-211 |
artikel |
32 |
Major Pharmaceutical Conferences and Courses
|
|
|
2016 |
|
3 |
p. 183-185 |
artikel |
33 |
Major Pharmaceutical Conferences and Courses
|
|
|
2018 |
|
3 |
p. 239-241 |
artikel |
34 |
Major Pharmaceutical Conferences and Courses
|
|
|
2015 |
|
3 |
p. 193-196 |
artikel |
35 |
Major Pharmaceutical Conferences and Courses
|
|
|
2014 |
|
3 |
p. 163-167 |
artikel |
36 |
Major Pharmaceutical Conferences and Courses
|
|
|
2013 |
|
3 |
p. 225-229 |
artikel |
37 |
Major Pharmaceutical Conferences and Courses
|
|
|
2019 |
|
3 |
p. 257-259 |
artikel |
38 |
Myths and Realities About Why Prescription Drug Prices in the United States Are So High
|
Lexchin, Joel |
|
2017 |
|
3 |
p. 143-148 |
artikel |
39 |
Nanoparticle-Mediated Delivery of Therapeutic Drugs
|
Ponnappan, Nisha |
|
2015 |
|
3 |
p. 155-167 |
artikel |
40 |
Nordic Health Registers as a Source for Value-Based Evidence
|
Flaten, Olav |
|
2014 |
|
3 |
p. 119-122 |
artikel |
41 |
Pharmacovigilance and Public Health Ethics
|
Callréus, Torbjörn |
|
2013 |
|
3 |
p. 157-164 |
artikel |
42 |
Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: Evaluation of Risk-Minimization Measures
|
Zografos, Laurie J. |
|
2019 |
|
3 |
p. 219-233 |
artikel |
43 |
Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector
|
Martinez-Grau, Maria Angeles |
|
2019 |
|
3 |
p. 193-198 |
artikel |
44 |
Quantitative Analysis of the Role of Patents and Drug Approvals in Drug Lifecycle Management in Japan
|
Yamanaka, Takayuki |
|
2016 |
|
3 |
p. 157-164 |
artikel |
45 |
Reflections on the Evolution of Patient Engagement in Drug Development
|
Getz, Kenneth |
|
2019 |
|
3 |
p. 179-185 |
artikel |
46 |
Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive
|
Borup, Rasmus |
|
2019 |
|
3 |
p. 199-207 |
artikel |
47 |
The Changing Face of Direct-to-Consumer Print Advertising
|
Macias, Wendy |
|
2010 |
|
3 |
p. 165-177 |
artikel |
48 |
The Francis Crick Institute: Scientific Discovery Open to Translation
|
Roblin, David |
|
2016 |
|
3 |
p. 133-135 |
artikel |
49 |
The Future of Pharmacovigilance: Proposals for More Efficient and Effective Systems-Based Approaches
|
Furlan, Giovanni |
|
2016 |
|
3 |
p. 137-142 |
artikel |
50 |
The revised Declaration of Helsinki: interpreting and implementing ethical principles in biomedical research
|
Pérez, Analia C. |
|
|
|
3 |
p. 131-143 |
artikel |
51 |
The Role of Health-Related Quality of Life Data in the Drug Approval Processes in the US and Europe
|
Marquis, Patrick |
|
2011 |
|
3 |
p. 147-160 |
artikel |
52 |
Using Social Media Data in Routine Pharmacovigilance: A Pilot Study to Identify Safety Signals and Patient Perspectives
|
Bhattacharya, Mondira |
|
2017 |
|
3 |
p. 167-174 |
artikel |
53 |
Value-Based Pharmaceutical Pricing From the Patient Perspective Could Incentivize Innovation
|
Koh, Cloe Ying C. |
|
2017 |
|
3 |
p. 149-153 |
artikel |